Indications

• Children's Trident SAP supports normal development of the brain, eyes, and nerves.

• Children's Trident SAP supports healthy cognitive function, reading, and learning.

• Children's Trident SAP supports healthy mood, attentiveness, and behavior.

• Children's Trident SAP promotes immune health and may prevent the risk of allergies.

Ingredients

Each chewable softgel contains:
Fish oil... 250 mg
Providing Eicosapentaenoic acid (EPA)... 100 mg
Docosahexaenoic acid (DHA)... 50 mg

From wild Atlantic deep sea fish oil: anchovy and sardine. Molecularly distilled.

Contains no: Preservatives, artificial flavor or color, sugar, dairy, wheat, gluten, corn, or
yeast.

Description

Omega 3 polyunsaturated fatty acids (PUFA) play a vital role in the healthy development and functioning of the brain and central nervous system in infants and children.
Docosahexaenoic acid [DHA, 22:6(n 3)] is the most abundant omega 3 PUFA in the
human brain, and it supports the normal development of the brain, eyes, and nerves.
Eicosapentaenoic acid [EPA, 20:5(n 3)] is the major precursor for eicosanoid metabolism, and it regulates neuronal and immune processes by influencing gene expression.
Numerous human observational and clinical trials support a link between childhood
neurodevelopmental and immune disorders with a deficiency of dietary EPA and
DHA, as well as omega 6:omega 3 PUFA imbalances. Currently, <10% of children meet recommended intakes of EPA+DHA. Therefore, supplementation of DHA as well as EPA is critical to support optimal neurocognitive, neurobehavioral, and immune function throughout childhood.

Quantity

120 chewable softgels

Dose

Children 1–13 years old and adolescents 14–18 years old: Take 1 softgel four times daily or as directed by your health care practitioner.

Potential side effects/Safety

EPA and DHA are essential fatty acids and are classified as generally recognized as safe (GRAS). Studies to date have found no significant adverse effects.

References

"Show references"

"Hide references"

1. Schuchardt, J.P., et al. “Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children”. European Journal of Pediatrics Vol. 169, No. 2 (2010): 149–164.
2. [No authors listed]. “Docosahexaenoic acid (DHA). Monograph”. Alternative Medicine Review Vol. 14, No. 4 (2009): 391–399.
3. Transler, C., et al. “The impact of polyunsaturated fatty acids in reducing child attention deficit and hyperactivity disorders”. Journal of Attention Disorders
Vol. 14, No. 3 (2010): 232–246.
4. Kremmyda, L.S., et al. “Atopy risk in infants and children in relation to early exposure to fish, oily fish, or long-chain omega-3 fatty acids: a systematic review”.
Clinical Reviews in Allergy & Immunology Vol.41, No.1 (2011): 36–66.
5. Protzko, J., J. Aronson, and C. Blair. “How to make a young child smarter: Evidence from the database of raising intelligence”. Perspectives on Psychological Science Vol. 8 (2013): 25-40.
6. Ryan, A.S. and E.B. Nelson. “Assessing the effect of docosahexaenoic acid on cognitive functions in healthy, preschool children: a randomized, placebo-controlled, double-blind study”. Clinical Pediatrics Vol. 47, No. 4 (2008): 355–362.
7. Richardson, AJ. and P. Montgomery. “The Oxford-Durham Study: A randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder”. Pediatrics Vol. 115, No. 5 (2005): 1360–1366.
8. Richardson, A.J., et al. “Docosahexaenoic acid for reading, cognition and behavior in children aged 7–9 years: A randomized, controlled trial (the DOLAB Study)”. PLoS One Vol. 7, No. 9 (2012): e43909.
9. Vancassel, S., et al. “Plasma fatty acid levels in autistic children”. Prostaglandins, Leukotrienes, and Essential Fatty Acids Vol. 65, No.1 (2001): 1–7.
10. Bell, J.G., et al. “Essential fatty acids and phospholipase A2 in autistic spectrum disorders”. Prostaglandins, Leukotrienes, and Essential Fatty Acids Vol.
71, No.4 (2004): 201–204.
11. Nemets, H., et al. “Omega-3 treatment of childhood depression: a controlled, double-blind pilot study”. The American Journal of Psychiatry Vol. 163, No.6 (2006): 1098–1100.
12. D'Vaz, N., et al. “Fish oil supplementation in early infancy modulates developing infant immune responses”. Clinical and Experimental Allergy Vol.42, No.8 (2012): 1206–1216.
13. Innis, S.M. “Omega-3 fatty acids and neural development to 2 years of age: Do we know enough for dietary recommendations?” Journal of Pediatric Gastroenterology and Nutrition Vol.48, Suppl.1 (2009): S16–S24. Erratum in
Journal of Pediatric Gastroenterology and Nutrition Vol. 50, No.2 (2010): 235. Dosage error in article text.
14. Ryan, A.S., et al. “Effects of long-chain polyunsaturated fatty acid supplementation on neurodevelopment in childhood: A review of human studies”.
Prostaglandins, Leukotrienes, and Essential Fatty Acids Vol. 82, No.4–6 (2010): 305–314.
15. Rhodes, D.G., et al. What we eat in America, Tables 1-36. Updated 2013-10-29. Retrieved from http://www.ars.usda.gov/Services/docs.htm?docid=18349
16. Kris-Etherton, P.M., S. Innis, American Dietetic Association, Dietitians of Canada. “Position of the American Dietetic Association and Dietitians of Canada: dietary fatty acids”. Journal of the American Dietetic Association Vol.
107, No.9 (2007): 1599–1611. Erratum in Journal of the American Dietetic Association Vol.107, No.12 (2007): 2151